Researchers at Icahn Mount Sinai found a new class of RNA in blood nanoparticles, potentially paving the way for less invasive cancer diagnosis. They used next-generation RNA sequencing and other innovative tools to develop a cost-effective liquid biopsy test to isolate and identify these novel RNA types.